Prostamol
Active Ingredients: Extr. Sabalis serrulatae
Therapeutic actions: Antiandrogenic drug. Prostamol depresses dihydrotestosterone synthesis and it’s fixation on citosolic receptors, which prevents hormone penetration in to the nucleus and leads to lowering of the protein synthesis. Diminishes the production of dihydrotestosterone, phospholipase A2 and arachidonic acid, decreases prostaglandin synthesis, which regulates tone and peristalsis of lower urinary tract. Possesses vaso-protective and anti-inflammatory effect, lowers vessel penetrtability. Antiandrogenic and vaso-protective effect promote symptom reduction of benign hypertrophy of the prostate gland.
Indications: Non-malign hyperplasia of the prostate gland.
Contraindications and cautions: Hypersensitivity.
Adverse effects: The following are some of the side effects that are known to be associated with this medicine. Because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect.
Vomiting, nausea if used on an empty stomach, allergic reactions.
The side effects listed above may not include all of the side effects reported by the drug's manufacturer.
Interactions: Tell your doctor or pharmacist what medicines you are already taking, including those bought without a prescription and herbal medicines, before you start treatment with this medicine.
Prostamol is compatible with antibiotics, urinal-antiseptics and anti-inflammatory drugs.
Chronic prostatitis affects 30-60% males and significantly deteriorates quality of their life. Clinical and experimental investigations have revealed changes in immune status in the onset and development of prostatic inflammation. As some other urologists, we made an attempt to determine the role of cellular immunity and immunoglobulins in the diagnosis of chronic prostatitis. The study was made in 30 patients with chronic abacterial prostatitis (mean age 42.5 years, duration of the disease 1.8 years). In addition to standard examination, all the patients have undergone analysis of the immune status and measurement of proinflammatory cytokines (TNF alpha and IL-12b) in biological media: blood serum, urine, ejaculate, prostatic secretion. The patients had moderate symptoms: IPSS--10.4 scores, life quality index--4.3 scores, on the average. Prostamol-uno was given to all the patients in a standard dose 1 capsule (320 mg) a day for 3 to 6 months. The results were processed statistically. A good effect of Prostamol-uno was registered in 26 patients, a satisfactory one--in 2. Two patients refused to take Prostamol-uno because of lack of a prominent effect. The scores of IPSS lowered from 10.4 to 6.3 (by 39%), life quality improved by 42%. Ultrasound monitoring of the size of the prostate showed no significant changes in the size. Tolerance was good in all 30 patients. Side effects were absent. After 3 months of the treatment serum, urine, ejaculate and prostatic secretion cytokines changed. TNF alpha elevated while IL-1 beta level lowered almost to normal value. In 6 months both IL-1 beta and TNF alpha returned to normal values confirming stabilization of cytokine system and the end of inflammation. Cellular immunity did not change much. Thus, as inflammation in prostatic tissue is characterized by elevation of proinflammatory cytokines, in diagnosis of chronic prostatitis it will be valid to use markers TNF alpha and IL-1 beta as criteria of immune prognosis of prostatic exacerbation. Prostamol-uno does not induce changes in lymphocyte populations and impairment of immune status.
Additional Information: DO NOT SHARE THIS MEDICINE with others. DO NOT USE THIS MEDICINE for other health conditions. KEEP THIS PRODUCT, as well as syringes and needles, if needed during treatment, out of the reach of children. Do not reuse needles, syringes, or other materials.